Abstract: Described herein are compositions for delivering a therapeutic or vaccine. Also described herein are methods for using the compositions described herein for delivering a therapeutic or a vaccine.

Abstract: Described herein are compositions for delivering a therapeutic or vaccine. Also described herein are methods for using the compositions described herein for delivering a therapeutic or a vaccine.

Abstract: Described herein are compositions for delivering a therapeutic or vaccine. Also described herein are methods for using the compositions described herein for delivering a therapeutic or a vaccine.

Abstract: Described herein are compositions for delivering a therapeutic or vaccine. Also described herein are methods for using the compositions described herein for delivering a therapeutic or a vaccine.

Abstract: Described herein are compositions for delivering a therapeutic. Also described herein are methods of using the compositions described herein for delivering a therapeutic.

Abstract: Nucleic acid sequences encoding improved Herpes Simplex Virus Thymidine Kinases are provided, including their use in diagnostic and therapeutic applications. The thymidine kinases may be mutated using conservative mutations, non-conservative mutations, or both. Also provided are gene therapeutic systems, including viral and retroviral particles.

Abstract: A portable pain treatment unit includes: a first pulse generator configured to deliver pulses in a frequency range typical for interferential treatment; a second pulse generator configured to deliver pulses in the frequency range for transcutaneous electrical nerve stimulator (TENS) treatment; electrodes operatively connected with the first and second pulse generators that are configured for application to a treatment area; and a power source operatively connected to the first and second pulse generators. A device of this configuration enables the patient to receive either IF or TENS treatment at a location of his/her choosing rather than being forced to receive IF treatment in a clinical setting.

Abstract: A portable pain treatment unit includes: a first pulse generator configured to deliver pulses in a frequency range typical for interferential treatment; a second pulse generator configured to deliver pulses in the frequency range for transcutaneous electrical nerve stimulator (TENS) treatment; electrodes operatively connected with the first and second pulse generators that are configured for application to a treatment area; and a power source operatively connected to the first and second pulse generators. A device of this configuration enables the patient to receive either IF or TENS treatment at a location of his/her choosing rather than being forced to receive IF treatment in a clinical setting.

Abstract: Methods and compositions for treating hyperproliferative diseases using combinations of one or more epothilones and one or more nucleoside analogs. In some embodiments, the combination includes epothilone D and 5-fluorouracil or 5′-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine.

Abstract: Formulations comprising one or more epothilones together with a pharmaceutically acceptable carrier, in particular such pharmaceutical compositions suitable for oral administration of an epothilone.

Abstract: A method and apparatus providing visual feedback to a computer user while dragging selected text is described. As its first step, the processing logic creates a text object from the selected text once the computer user has initiated a drag. Simultaneously, the selected text is visually de-emphasized. Secondly, the processing logic snaps the text object to the cursor so that the text object follows the cursor without obscuring text at the insertion point. Finally, when the computer user selects the final insertion point, the selected text is visually zoomed from the source location to the final insertion point.

Abstract: Methods to deliver epothilone D to subjects having tumorigenic diseases are provided.

Abstract: A coupler for connecting a first, slotted, implanted spinal fixation element to a second spinal fixation element includes a post and a head disposed on a distal end of the post. The head of the coupler has a width shorter than a width of a slot in the first, slotted, implanted spinal fixation element, and a length longer than the width of the slot in the first, slotted, implanted spinal fixation element. The coupler with a head so configured can be placed in a first orientation so that the head passes through the slot in the first, slotted, implanted spinal fixation element, and then can be placed in a second orientation wherein the head is trapped beneath the first, slotted, implanted spinal fixation element while the post having a connecting element extends through the slot. Systems and methods for extending a first, implanted spinal fixation element to one or more additional vertebrae while leaving the first, implanted spinal fixation element in place are also disclosed.

Abstract: A coupler for connecting a first, slotted, implanted spinal fixation element to a second spinal fixation element includes a post and a head disposed on a distal end of the post. The head of the coupler has a width shorter than a width of a slot in the first, slotted, implanted spinal fixation element, and a length longer than the width of the slot in the first, slotted, implanted spinal fixation element. The coupler with a head so configured can be placed in a first orientation so that the head passes through the slot in the first, slotted, implanted spinal fixation element, and then can be placed in a second orientation wherein the head is trapped beneath the first, slotted, implanted spinal fixation element while the post having a connecting element extends through the slot. Systems and methods for extending a first, implanted spinal fixation element to one or more additional vertebrae while leaving the first, implanted spinal fixation element in place are also disclosed.

Abstract: A method of treating wounds includes the step of applying UVC radiation to the wound for a time and at a proximity and intensity sufficient to have a bacteriocidal effect. The method is particularly effective when carried out with a UVC lamp having an intensity of between 5 and 20 &mgr;W/cm2, with a duration of between about 5 seconds and 1 minute and a proximity to the wound of between about ¼ and 3 inches from the wound being preferred. It has been observed that such application of UVC radiation can kill up to 100 percent of the microorganisms present in a wound, thereby enabling the wound to heal free of infection.

Abstract: The invention concerns recombinant human adenosine receptors A1, A2a, A2b and A3 which have been prepared by cDNA cloning and polymerase chain reaction techniques. The invention also concerns expression systems for these receptors and an assay using the expression systems. The recombinant adenosine receptors comprising the invention can be utililized in an assay to identify and evaluate entities that bind to or enhance binding to adenosine receptors.

Abstract: The invention concerns recombinant human adenosine receptors A1, A2a, A2b and A3 which have been prepared by cDNA cloning and polymerase chain reaction techniques. The invention also concerns expression systems for these receptors and an assay using the expression systems. The recombinant adenosine receptors comprising the invention can be utililized in an assay to identify and evaluate entities that bind to or enhance binding to adenosine receptors.

Abstract: The invention concerns the identification on eosinophils of the A3 adenosine receptor subtype and the blockade of said receptor in order to achieve inhibition of eosinophil activation and degranulation.

Abstract: The invention concerns recombinant human adenosine receptors A1, A2a, A2b and A3 which have been prepared by cDNA cloning and polymerase chain reaction techniques. The invention also concerns expression systems for these receptors and an assay using the expression systems. The recombinant adenosine receptors comprising the invention can be utilized in an assay to identify and evaluate entities that bind to or enhance binding to adenosine receptors.

Abstract: A two-level IR detector imaging array of high fill-factor design. The upper microbridge detector level is spaced above and overlie the integrated circuit and bus lines on the substrate surface below.